berzosertib
-
September 9, 2020
What’s New in Treatment for Castrate-Resistant Prostate Cancer?
Emma Shtivelman, PhDAbout 10% to 20% of all prostate cancers are classified as castrate-resistant prostate cancer (CRPC). CRPC occurs when prostate cancer evolves to resist standard treatment with androgen deprivation therapy (ADT), which blocks the production and signaling activity of hormones called… Read more »